Sarepta Therapeutics (NASDAQ:SRPT) Given New $99.00 Price Target at Deutsche Bank Aktiengesellschaft

Sarepta Therapeutics (NASDAQ:SRPT) had its price target reduced by investment analysts at Deutsche Bank Aktiengesellschaft from $124.00 to $99.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 34.62% from the company’s previous close.

Several other brokerages have also recently issued reports on SRPT. Needham & Company LLC restated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Tuesday. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday. Finally, Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $168.55.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $73.54 on Wednesday. The company has a 50 day simple moving average of $110.18 and a two-hundred day simple moving average of $119.13. Sarepta Therapeutics has a fifty-two week low of $73.06 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market capitalization of $7.14 billion, a price-to-earnings ratio of 58.83 and a beta of 0.79.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares during the last quarter. Sunbelt Securities Inc. grew its position in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank grew its position in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.